Party Preamble. Patents 1.1(oo) Payment Agent 2.9(a) Per Share Price 2.7(a)(ii) Permits 3.20 Proxy Statement 6.3(a) Real Property 3.14(b) SEC Reports Article III Redemption 6.5(c) Requisite Stockholder Approval 3.4 Schedule 13E-3 6.3(b) Service Proration 6.10(f) Special Committee Recitals Sublease 3.14(c) Surviving Corporation 2.1 Tax Returns 3.17(a) Termination Date 8.1(c) Uncertificated Shares 2.9(c) Voting Agreement Recitals
Party Preamble. Personal Property Lease Assignments Section 2.11(b)(iii) Proceeds Section 8.15(a)(i) Property Financial Statements Section 4.7(e) Proxy Statement Seventh Recital PST Act Section 3.6(a)(i) PST Clearance Certificate Section 3.6(a)(i) Purchased Assets Fourth Recital Defined Term SECTION NO. Purchaser Preamble Purchaser Leases Section 6.15(g) Purchaser Permitted Liens Section 6.15(a) Purchaser Properties Section 6.15(a) Purchaser Property Section 6.15(a) Purchaser Termination Amount Section 10.3(a)(v) Purchasers Preamble Qualifying Income Section 10.3(d)(i) Release Agreement Section 2.11(b)(xiii) Release Costs Section 8.7(g) Remittance Deadline Section 3.5(c) Sale Seventh Recital Sales Tax Escrow Agreement Section 3.6(a)(ii) Section 167 Election Section 8.12(e)(i) Seller Preamble Seller Disclosure Letter Article 4 Seller Parties Preamble Seller Party Preamble Sellers Preamble Series A Preferred Shares Section 6.2(a) Series B Preferred Shares Section 6.2(a) Series C Preferred Shares Section 6.2(a) Series D Preferred Shares Section 6.2(a) Series E Preferred Shares Section 6.2(a) Series F Preferred Shares Section 6.2(a) Ski Equity Sellers Preamble Ski Parties Section 8.7(b) Ski Purchased Assets Third Recital Ski Purchaser Preamble Ski Purchaser Asset Sale Third Recital Ski Purchaser Closing Cash Consideration Section 3.1(a)(i) Ski Purchaser Closing Consideration Section 3.1(a)(i) Ski Purchaser Equity Interests Third Recital Ski Purchaser Interest Sale Third Recital Ski Purchaser Manager Ninth Recital Ski Target Companies Second Recital SST Act Section 3.6(a)(ii) SST Clearance Certificate Section 3.6(a)(ii) Subleases Section 4.16(f) Superior Proposal Section 8.6(i)(ii) Takeover Statutes Section 4.20 Target Companies Second Recital Target Company Insurance Policies Section 4.18 Target Company Permits Section 4.6(b) Target Company Subsidiary Section 4.1(e) Target Company Title Insurance Policies Section 4.16(m) Defined Term SECTION NO. Target Company Title Insurance Policy Section 4.16(m) Tenant Estoppel Bring-Down Letters Section 8.18 Tenant/Manager Insurance Policies Section 4.18 Trademark Assignment Agreement Section 2.11(b)(v) Transfer Taxes Section 8.12(a) TRS Distribution Section 8.10 ULC Canadian Asset Sale Third Recital U.S. Ancillary Asset Sale Documents Section 2.11(b)(vi) U.S. Asset Sellers Preamble U.S. Asset Assignment Agreements Section 2.11(b)(i) U.S. Assumed Liabilities Section 2.5(a)(iii) U.S. Attractions Asset Sellers Preamble U.S. Attractions Owne...
Party Preamble. Patents 1.1(uu) Payment Agent 2.9(a) Payoff Letters 6.20 Per Share Price 2.7(a)(ii) Permits 3.20 Prohibited Modifications 6.5(a) Recent SEC Reports Article III Recommendation Change 5.3(c)(i) Reimbursement Obligations 6.6(f) Reinvestment Stockholders Recitals Repaid Indebtedness 6.20 Representatives 5.3(a) Required Amount 4.11(c) Rollover Shares Recitals Schedule 13e-3 6.3(a) Schedule 14D-9 2.16(b)(i) Schedule TO 2.15(f)(i) Special Committee Recitals Special Committee Advisor 3.3(c) Special Committee Recommendation 3.3(a) Stockholder List Date 2.17 Surviving Corporation 2.1 Tender and Support Agreements Recitals Termination Date 8.1(c) Uncertificated Shares 2.9(c) Written 1.3(s)
Party Preamble. Article III Activities Section 3.3(a) Pfenex Preamble Assisting Party Section 3.4(e) Pfenex Indemnitees Section 11.2 Bankruptcy Code Section 12.15 Pfenex Profit Share Section 4.4 Commercial Territory Section 5.8(a) Product Financial Records Section 4.7 Commitment Activities Section 3.2(e) Product Inventions Section 6.2 Common Interest Agreement Section 6.9 Product License Section 2.1 Confidential Information Section 8.1 Product Records Section 3.3(d) Confidentiality Exceptions Section 8.1 PTO Section 6.3(a) Cooperating Party Section 6.5(d) PV Agreement Section 3.3(e) [***]Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
Party Preamble. Exchange Fund 2.01 Patents 3.25(i)
Party Preamble. Final POC Trial Report 3.6.2.1 Patent Prosecution and Enforcement Committee 5.2.1 Final Pre-Clinical Report 3.5.2.2 ImmTOR Recitals Permitted Deductions 1.50 IND Enabling Studies 3.5.1.1 Pharmacovigilance Agreement 4.2.3.7 Indemnified Party 10.3.1 POC Budget 3.6.1.2 Indemnifying Party 10.3.1 POC Candidate(s) 3.1 Initial POC Trial Report 3.6.2.1 POC Clinical Trials 3.5.1.1 JAMS 12.4 POC Cost Report 3.4 JCC 5.2.3 POC Costs 3.3 JDC 5.2.2 POC Determination Deadline 3.7.3 JFC 5.2.4 POC Notice 3.8 Joint Commercialization Committee 5.2.3 POC Plans 3.6.1.1 POC Studies 3.1 Joint Development Committee 5.2.2 POC Trial Reports 3.6.2.1 Joint Finance Committee 5.2.4 Potential Partnership 4.2.8.2 Joint Improvements 8.2.1 PPEC 5.2.1 Joint Inventions 8.2.2 Pre-Clinical Plan 3.5.1.1 Joint Patent Right Infringement 8.4.1 Pre-Clinical Plan Budget 3.5.1.3 Joint Steering Committee 5.1.1 Pre-Clinical Plan Timeline 3.5.1.2 Joint Venture Recitals Preliminary Pre-Clinical Report 3.5.2.1 JSC 5.1.1 Preparing Party 6.2.3 JSC Co-Chairs 5.1.2 Product 3.1 JV Recitals Profit Share Percentage 6.2.1 KOL 4.2.3.1 Proposed Study(ies) 4.2.2.5 Licensed Patent Right Infringement 8.4.1 Proposing Party 4.2.2.5 Prosecuting Party 8.3.3.6 [***] [***] Publications Policy 7.4 Losses 10.1 Reconciliation Report 6.2.3 [***] [***] Regulatory Lead Party 4.2.3.1 Non-Proposing Party 4.2.2.5 -13- Definition Section Definition Section Representatives 7.1 Subcommittee 5.1.2 Research Licenses 8.1.2 Summary Statement 6.2.2 Rules 12.4 Term 11.1 Selecta Preamble Therapeutic Development Plan 4.2.2.1 Selecta Collaboration Product License 8.1.3.1.1 Therapeutic Development Plan Budget 4.2.2.1 Selecta Improvements 8.2.1 Therapeutic Development Plan Timeline 4.2.2.1 Selecta Indemnified Party 10.1 Selecta Inventions 8.2.2 Therapeutic POC Candidate 3.1 Selecta Research License 8.1.2 Third Party Claims 10.1 Study Data 4.2.3.2 Viralgen 1.4 Study Results 3.7.2 Withholding Party 6.5 Working Group 5.3
Party Preamble. Patents 1.1 Paying Agent 3.2 (a) Property 4.13 (b) Purchaser Preamble Purchaser Affiliate 4.4 (c) Purchaser Disclosure Schedule Article V Purchaser Expenses 8.2 (c) Purchaser Termination Fee 8.2 (b)(ii) Recommendation 4.20 (a) Representatives 6.4 (a) Restraints 7.1 (e) Returns 4.12 (a) SEC 4.4 (a) Severance Pay Law 1.1 Subsidiary Shares 4.2 (c) Substantial Creditors 6.6 (b)(ii) Superior Proposal 6.5 (g) Surviving Company 2.1 Surviving Company Articles 2.4 Tail Policy 6.12 (b) Trademarks 1.1 Trade Secrets 1.1 Transactions Recitals URLs 1.1
Party Preamble. Patents 1.1 Payment Agent 2.9(a) Per Share Price 2.7(a)(ii) Permits 3.20 Privacy Laws 3.16(h) Proposal Notice Period 5.3(e)(ii)(3) Protected Information 3.16(h) Proxy Statement 6.3(a) Representatives 5.3(a) Required Amount 4.12(d) Requisite Stockholder Approval 3.4 RSU Consideration 2.8(a)(i) SEC Clearance Date 6.3(g) Specified Acquisition 5.4 Sublease 3.14(c) Surviving Corporation 2.1 Tax Proceeding 3.17(c)
Party Preamble. Patents 1.1 Payor 3.3(i)(i) Privacy Policies 4.12 Proxy Statement 7.1(a) Qualified Withholding Certificate 3.3(i)(ii) recipient 3.3(i)(iv) Registration Statement 7.1(a) Section 14 Arrangement 5.18(e) Securityholder 3.3(i)(ii) Shell Company 5.23 Surviving Company 2.1(a) Surviving Company Articles 2.3 Termination Notice Period 9.1(h) Transfer Taxes 7.12(e) Withholding Drop Date 3.3(i)(ii) Withholding Tax Ruling 3.3(k)
Party Preamble. Patents 1.1(hhh) Payment Agent 2.9(a) Payment Fund 2.9(b) Payoff Letters 6.6(c)(i) Per Share Price 2.7(a)(ii) Proxy Statement 6.3(a) Remedial Action 6.2(b) Requisite Stockholder Approval 3.4 Section 721 6.2(c) Surviving Corporation 2.1 Tail Policy 6.10(c) Termination Date 8.1(c) Uncertificated Shares 2.9(c) Unvested Equity Awards 2.8(e) Vested Equity Award Consideration 2.8(e) Vested Equity Awards 2.8(e)
